NXTCL logo

NextCell Pharma AB Stock Price

OM:NXTCL Community·SEK 78.1m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

NXTCL Share Price Performance

SEK 0.70
-1.82 (-72.18%)
SEK 0.70
-1.82 (-72.18%)
Price SEK 0.70

NXTCL Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

6 Risks
1 Reward

NextCell Pharma AB Key Details

SEK 11.1m

Revenue

SEK 9.4m

Cost of Revenue

SEK 1.7m

Gross Profit

SEK 36.8m

Other Expenses

-SEK 35.1m

Earnings

Last Reported Earnings
Aug 31, 2025
Next Reporting Earnings
n/a
-0.32
15.07%
-317.62%
0%
View Full Analysis

About NXTCL

Founded
2014
Employees
24
CEO
Mathias Svahn
WebsiteView website
www.nextcellpharma.com

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of novel stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cells for the treatment of autoimmune and inflammatory diseases, including type-1 diabetes. The company also operates Cellaviva, a stem cell bank. The company was incorporated in 2014 and is headquartered in Huddinge, Sweden.

Recent NXTCL News & Updates

Recent updates

No updates